^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug Class: | HER2 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Published date:
09/22/2023
Excerpt:
Among HER2 3 + BC patients, administration of adjuvant anti-HER2 in addition to chemotherapy significantly increased 10-year survival (P < 0.001 and P = 0.006, for BCSS and DMFS, respectively)....In HER2 + BC, overexpression of HER2 protein is the driver of the oncogenic pathway, and it is the main predictor of response to anti-HER2 therapy.
DOI:
https://doi.org/10.1038/s41416-023-02426-4